HMGN2 Antibody [F23H15]

Catalog No.: F6287

Application: Reactivity: Human

Lane 1: HL60, Lane 2: K562, Lane 3: Hela, Lane 4: SH-SY5Y

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000-1:10,000 IHC1:250-1:500

Application
WB, IHC

Source
Rabbit Monoclonal Antibody

Reactivity
Human

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
9 kDa 18 kDa
^*なぜ予測分子量と実際の分子量が異なるのか？下記の原因により、実際の分子量が予測と異なる：タンパク質の翻訳後修飾（リン酸化/糖鎖付加），スプライシングバリアント，イソフォーム，相対的な電荷，ポリマー。

Datasheet & SDS

生物学的記述

Specificity
HMGN2 Antibody [F23H15] detects endogenous levels of total HMGN2 protein.

Clone
F23H15

Synonym(s)
HMG17; HMGN2; Non-histone chromosomal protein HMG-17; High mobility group nucleosome-binding domain-containing protein 2

Background
HMGN2 (High Mobility Group Nucleosome‑binding domain 2) is a small, non‑histone chromosomal protein of the HMGN family that binds directly to the nucleosome core particle and modulates chromatin structure and function. It is widely expressed in multiple tissues and is recruited to nucleosomes by interacting with the acidic patch of the H2A–H2B dimer and with nucleosomal DNA near the dyad‑entry/exit regions, partially displacing linker histone H1 and altering nucleosome spacing and higher‑order folding. Through these interactions, HMGN2 influences chromatin accessibility and histone modification patterns, including the enhancement of certain histone acetylation marks, and thereby regulates the binding of transcription factors and the activity of transcriptional enhancers and promoters. HMGN2 also associates with transcription factors such as Lef‑1 and Pitx2, and can inhibit their DNA‑binding and transcriptional activation, positioning it as a chromatin‑linked modulator of lineage‑specific gene programs during development and differentiation. HMGN2 is detectable in the extracellular milieu under inflammatory or cytotoxic conditions and can act as an effector‑type protein in immune cells, where it has been reported to inhibit tumor‑cell proliferation and migration, induce apoptosis, and sensitize cancer cells to chemotherapeutic agents. Altered HMGN2 expression or localization is observed in several cancers, where it can correlate with reduced proliferation, migration, and tumor growth, and HMGN2‑deficiency studies further link it to changes in innate immune responses and chromatin‑dependent macrophage reprogramming.

Background

HMGN2 (High Mobility Group Nucleosome‑binding domain 2) is a small, non‑histone chromosomal protein of the HMGN family that binds directly to the nucleosome core particle and modulates chromatin structure and function. It is widely expressed in multiple tissues and is recruited to nucleosomes by interacting with the acidic patch of the H2A–H2B dimer and with nucleosomal DNA near the dyad‑entry/exit regions, partially displacing linker histone H1 and altering nucleosome spacing and higher‑order folding. Through these interactions, HMGN2 influences chromatin accessibility and histone modification patterns, including the enhancement of certain histone acetylation marks, and thereby regulates the binding of transcription factors and the activity of transcriptional enhancers and promoters. HMGN2 also associates with transcription factors such as Lef‑1 and Pitx2, and can inhibit their DNA‑binding and transcriptional activation, positioning it as a chromatin‑linked modulator of lineage‑specific gene programs during development and differentiation. HMGN2 is detectable in the extracellular milieu under inflammatory or cytotoxic conditions and can act as an effector‑type protein in immune cells, where it has been reported to inhibit tumor‑cell proliferation and migration, induce apoptosis, and sensitize cancer cells to chemotherapeutic agents. Altered HMGN2 expression or localization is observed in several cancers, where it can correlate with reduced proliferation, migration, and tumor growth, and HMGN2‑deficiency studies further link it to changes in innate immune responses and chromatin‑dependent macrophage reprogramming.

References
[1] Eliason S, et al. J Biol Chem. 2022 Sep;298(9):102295. [2] Liang G, et al. Oncol Rep. 2015 Mar;33(3):1300-6.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%